Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulin glulisine.

Sandra L Cox1

  • 1Medical Information Department, Prous Science, Barcelona, Spain.

Drugs of Today (Barcelona, Spain : 1998)
|September 30, 2005
PubMed
Summary
This summary is machine-generated.

Insulin glulisine, a rapid-acting insulin analog, offers improved glycemic control for diabetes patients. It effectively manages postmeal glucose levels with a safety profile comparable to regular human insulin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tesaglitazar: a promising approach in type 2 diabetes.

Drugs of today (Barcelona, Spain : 1998)·2006
Same author

Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.

Drugs of today (Barcelona, Spain : 1998)·2005
Same author

Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.

Drugs of today (Barcelona, Spain : 1998)·2005
Same author

Emtricitabine: a novel nucleoside reverse transcriptase inhibitor.

Drugs of today (Barcelona, Spain : 1998)·2005
Same author

Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.

Drugs of today (Barcelona, Spain : 1998)·2004
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Conventional insulin therapy in diabetes can be limited in achieving tight glycemic control, increasing the risk of long-term complications.
  • Recombinant insulin analogs represent advancements in diabetes management.
  • Insulin glulisine is a novel rapid-acting insulin analog designed for improved pharmacokinetic properties.

Purpose of the Study:

  • To review the clinical efficacy and safety of insulin glulisine.
  • To compare insulin glulisine's profile with regular human insulin.

Main Methods:

  • Review of current clinical data on insulin glulisine.
  • Analysis of pharmacokinetic and pharmacodynamic properties.
  • Evaluation of safety and efficacy in type 1 and type 2 diabetes.

Related Experiment Videos

Main Results:

  • Insulin glulisine demonstrates faster absorption, quicker onset, and shorter duration compared to regular human insulin.
  • Effective postprandial glucose control in both type 1 and type 2 diabetes without increased hypoglycemia risk.
  • Equivalent glucose-lowering effect per unit compared to regular human insulin.

Conclusions:

  • Insulin glulisine offers a valuable therapeutic option for diabetes management.
  • Its pharmacokinetic profile allows flexible administration timing (pre- or post-meal).
  • Favorable safety profile supports its use in clinical practice.